<DOC>
	<DOCNO>NCT01598740</DOCNO>
	<brief_summary>The purpose study determine effect CLP , without spironolactone , serum , urine , fecal content heart failure patient chronic kidney disease .</brief_summary>
	<brief_title>Evaluation CLP With Without Spironolactone Heart Failure Patients With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Heart failure New York Heart Association ( NYHA ) Classification II III Chronic kidney disease Cardiac ejection fraction &lt; 40 % On heart failure therapy include ACEI ARB , BB Willing understand comply study procedure provide write informed consent . Hospitalization within 4 week baseline visit History presence gastrointestinal condition severe constipation gastrointestinal tract strictures Current anticipated dialysis study In investigator 's judgment , cardiovascular , renal , hepatic , endocrine , gastrointestinal , neurological , disease condition make subject 's study participation unsafe Drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>